Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries, a microcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high of Rs.126.75 on November 27, 2024. The company's strong performance in the market, outperforming the sector by 4.15%, has contributed to this increase. The stock has been on a consecutive upward trend for the past 3 days, with a significant increase of 53.47%. It is currently trading above its moving averages, indicating a positive trend. With a remarkable 1-year performance of 56.59%, Krebs Biochemicals & Industries shows strong growth and potential in the pharmaceutical industry.

Krebs Biochemicals & Industries, a microcap pharmaceutical company, has reported a flat performance in the second quarter of fiscal year 2024-2025. The company's annual operating cash flow has increased, but its PBT and net sales have decreased significantly. Investors should carefully evaluate these factors before making any investment decisions.

Krebs Biochemicals & Industries has announced its financial results for the quarter ending March 2024, with a score of 3 out of 5. Despite a 'Sell' call from MarketsMOJO, the company has shown positive trends in net sales, operating profit, and net profit, indicating potential for future growth in the pharmaceutical industry.

Krebs Biochemicals & Industries, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 19, 2024. The company's consistent growth and positive market sentiment have contributed to this success, with the stock outperforming the sector and the Sensex. While there is some volatility, the company's strong performance and potential for growth make it a promising player in the pharmaceutical industry.

Krebs Biochemicals & Industries, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on July 18th, 2024. Despite a 'Sell' call from MarketsMOJO, the company has outperformed its sector and has been on a consecutive gain streak for the past 5 days. It is currently trading above its moving averages and has shown a 19.44% increase in the past year, showcasing its stability and potential for growth in the pharmaceutical industry.

Krebs Biochemicals & Industries Ltd, a microcap pharmaceutical company, saw its stock reach a 52-week high on July 9, 2024. Despite a recent dip, the stock has shown strong performance over the past year and is trading higher than its moving averages. Investors should conduct their own research before making any investment decisions.

Krebs Biochem has reported a positive growth in operating profit, net profit, and EPS for the half yearly period, with a return on capital employed of 12.19% and a healthy debt to equity ratio of 0.02. However, MarketsMOJO has given a 'Strong Sell' call for the company's stock, indicating caution for potential investors.

Krebs Biochemicals & Industries, a microcap pharmaceutical company, has reported a flat performance in the quarter ending December 2023, with a score of 0 compared to -6 in the previous quarter. However, net sales have shown a strong growth of 42.79%, while interest expenses have also increased by 28.09%. Investors should carefully evaluate these factors before investing.

Krebs Biochemicals & Industries reported a 40.74% increase in net sales and a 33.02% growth in standalone net profit for the quarter ended September 2023. However, the company's overall financial performance was negative, with a score of -6. MarketsMOJO has given a 'Strong Sell' call, citing declining sales and cash flow.